Table 1 Clinicopathologic features, treatment modalities, and follow-up data of SCTAT cases

1

18

26

^aRSO

Right:-

^aTAH + LSO + RTR + LN biopsy

PVB*3

2

-

146

DOD

2

31

34

^aLSO

Left:7 cm

^aTAH + RSO + omentum + LND + RTR+ RPL

5-Fu*1,N-formylsarcolysin *5,TSPA*2

3

Chemo: PVB*4; ^aRTR + RPL + RT

179

PR

3

15

15

No

Right:30 cm

^aRSO

nitrosourea

0

-

84

CR

4

8

8

No

Left:9 cm

^aLSO + biopsy of right ovary

-

0

-

48

CR

5

31

31

No

right:13 cm;left:microscopic

^aRSO and biopsy of left ovary

-

0

-

24

CR

6

21

29

^aRSO

Right:24 cm

^aTAH + LSO + RTR  + omentum

PVB*2

3

^aRTR;RT

143

PR

7

18

20

^aLSO; RTR + RPL + RT + Chemo

Left:20 cm

^aRTR + RPL + LND

PEB*3

2

-

26

CR

8

39

39

No

Right:5 cm

^bRSO and biopsy of left ovary

-

0

-

55

CR

9

6

6

^aBiopsy of ovary

Left:8 cm

^aLSO

-

0

-

63

CR

10

39

39

No

Right:12 cm

^aTAH + BSO + LND + omentum

PEB*3

0

-

107

CR

11

29

30

^aLSO

Left:6 cm

^aRTR + RPL + LND

PEB*3

1

-

21

CR

12

34

34

No

Right:12⁺cm

^bCystectomy

-

3

^aRSO + RTR + omentum + appendix; RTR^a + chemo; RTR^a

51

PR

13

5

5

No

Left:8 cm

^bBiopsy of ovary; ^bLSO

-

0

-

20

CR